IGC Pharma, Inc. (IGC) vs Kyntra Bio Inc (KYNB)

IGC Pharma, Inc. and Kyntra Bio Inc are both Biotechnology companies. IGC Pharma, Inc. and Kyntra Bio Inc are of similar size ($29.1M and $28.3M). IGC Pharma, Inc. has negative trailing earnings, so its P/E is not meaningful; Kyntra Bio Inc trades at 0.2×. IGC Pharma, Inc. grew revenue faster over the last twelve months: −13.4% against −37.2%. Kyntra Bio Inc has the higher net margin (3,967.8% vs −795.5%) and the higher return on invested capital (0.00% vs −91.5%). Across the 17 metrics below, Kyntra Bio Inc leads on 9 and IGC Pharma, Inc. on 8.

Valuation

Metric IGC KYNB Biotechnology median
P/E n/m 0.15 7.88
P/S 25.52 6.08 11.47
P/B 4.58 n/m 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 26.18 18.18 10.73
Earnings yield (32.14%) 652.74% (28.84%)
Free cash flow yield (20.24%) (135.59%) (23.03%)

Profitability

Metric IGC KYNB Biotechnology median
Gross margin 32.33% 6.28% 65.16%
Operating margin (912.44%) (1,089.78%) 0.00%
Net margin (795.46%) 3,967.77% 0.00%
Free cash flow margin (516.53%) (824.19%) 0.00%
Return on equity (143.46%) (157.83%) (57.72%)
Return on assets (100.44%) 131.26% (49.22%)
Return on invested capital (91.53%) 0.00% 0.00%

Growth

Metric IGC KYNB Biotechnology median
Revenue growth (TTM) (13.38%) (37.15%) 5.64%
EPS growth (last fiscal year) 57.85% 478.08% —
Revenue growth, 5-year CAGR (20.77%) (48.42%) 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric IGC KYNB Biotechnology median
Debt to equity 0.18 0.00 0.00
Current ratio 0.39 2.69 4.73
Net debt to EBITDA 0.04 1.97 0.96

Dividend

Metric IGC KYNB Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric IGC KYNB Biotechnology median
Market cap 29.11m 28.34m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack